Search

Your search keyword '"Biglan, K. M."' showing total 16 results
Start Over Author "Biglan, K. M."
16 results on '"Biglan, K. M."'

4. Inaugural Huntington Disease Clinical Research Symposium Organized by the Huntington Study Group

Author

Moser, Katharine, Biglan, K. M., Ross, C. A., Langbehn, D. R., Aylward, E., Stout, J. C., Queller, S., Carlozzi, N., Duff, K., Beglinger, L. J., Paulsen, J. S., Tomusk, A., Lifer, S., Hastings, S., Dawson, J., Walker, B., Whitlock, K., Johnson, S., Pacifici, Robert, Hersch, S., Dorsey, E. R., Katz, Russell, Tempkin, T., Wheelock, V., Schwartz, G., Corey-Bloom, J., Mattis, P., Feigin, A., Young, P., McArthur, D. L., Perlman, S., Higginson, C., Carr, L., Sigvardt, K., Chirieac, M. C., Shinaman, A., Shoulson, I., Kane, A. E., Peavy, G. M., Goldstein, J. L., Jacobson, M. W., Lessig, S., Wasserman, L., Kayson, E. P., Tang, C., Zgaljardic, D., Ma, Y., Dhawan, V., Guttman, M., Eidelberg, D., Peng, S., Kingsley, P., Rosas, H. D., Gevorkian, S., Oakes, D., Matson, W., Massood, T., Latourelle, J., Mysore, J. Srinidhi, Fossale, E., Gillis, T., Gusella, J. F., MacDonald, M. E., Myers, R. H., Yastrubetskaya, O., Preston, J., Chiu, E., Goh, A., Oster, E., Bausch, J., Kayson, E., Quaid, K., Sims, S., Swenson, M., Harrison, J., Moskowitz, C., Stepanov, N., Suter, G., Westphal, B., Johnson, S. A., Langbehn, D., Paulsen, J., Nopoulos, P., Beglinger, L., Johnson, H., Magnotta, V., Pierson, R., Lipe, H., Bird, T. D., McCusker, E. A., Lownie, A., Lechich, A. J., Montas, S., Duckett, A., Klager, J., Sandler, S., Pae, A., Apostol, B. L., Simmons, D. A., Zuccato, C., Illes, K., Pallos, J., Casale, M., Kathuria, S., Cattaneo, E., Marsh, J. L., Thompson, L. Michels, Patzke, H., Chesworth, R., Li, Z., Rahil, G., Wang, J., Smith, J., Huet, F. L., Shapiro, G., Leit, S., Beaulieu, P., Raeppel, F., Fournel, M., Sainte-Croix, H., Nolan, S. J., Albayya, F. P., Barbier, A., Besterman, J., Ahlijanian, M. K., Deziel, R., Aubeeluck, A., Buchanan, H., Ross, C., Biglan, K., Landwehrmeyer, B., Whitlock, K. B., Carlozzi, N. E., Mickes, L., Lee, J., Kim, R. Y., Di Toro, B., Fine, E., Cahill, T., Johnson, D., Goldstein, J., Peavy, G., Jacobson, M., Goodman, L. Veatch, Como, P. G., Cha, J. H., Beck, C., Adams, M., Chadwick, G., de Blieck, E. A., McCallum, C., Deuel, L., Clarke, A., Stewart, R., Adams, W. H., Paulson, H., Fiedorowicz, J. G., Hanson, J. M., Ramza, N., Priller, J., Ecker, D., PREDICT-HD Investigators of the Huntington Study Group, Huntington Study Group CoHort Investigators, Huntington Study Group PHAROS Investigators, PREDICT-HD Investigators and Coordinators of the Huntington Study Group, Huntington Study Group TREND-HD Investigators, and EHDN Working Group ‘Symptomatic Treatment.’

Published
2008
Full Text
View/download PDF

14. Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030

Author

Dorsey, E R., Constantinescu, R, Thompson, J P., Biglan, K M., Holloway, R G., Kieburtz, K, Marshall, F J., Ravina, B M., Schifitto, G, Siderowf, A, and Tanner, C M.

Abstract

Based on published prevalence studies, we used two different methodologies to project the number of individuals with Parkinson disease (PD) in Western Europe’s 5 most and the world’s 10 most populous nations. The number of individuals with PD over age 50 in these countries was between 4.1 and 4.6 million in 2005 and will double to between 8.7 and 9.3 million by 2030.

Published
2007
Full Text
View/download PDF

15. Detecting and monitoring the symptoms of Parkinson's disease using smartphones: A pilot study.

Author

Arora S, Venkataraman V, Zhan A, Donohue S, Biglan KM, Dorsey ER, and Little MA

Subjects
Aged, Female, Fingers, Humans, Male, Middle Aged, Parkinson Disease physiopathology, Pilot Projects, Posture, Reaction Time physiology, Sensitivity and Specificity, Severity of Illness Index, Telemedicine, Voice, Gait, Motor Skills, Parkinson Disease diagnosis, Smartphone instrumentation
Abstract

Background: Remote, non-invasive and objective tests that can be used to support expert diagnosis for Parkinson's disease (PD) are lacking., Methods: Participants underwent baseline in-clinic assessments, including the Unified Parkinson's Disease Rating Scale (UPDRS), and were provided smartphones with an Android operating system that contained a smartphone application that assessed voice, posture, gait, finger tapping, and response time. Participants then took the smart phones home to perform the five tasks four times a day for a month. Once a week participants had a remote (telemedicine) visit with a Parkinson disease specialist in which a modified (excluding assessments of rigidity and balance) UPDRS performed. Using statistical analyses of the five tasks recorded using the smartphone from 10 individuals with PD and 10 controls, we sought to: (1) discriminate whether the participant had PD and (2) predict the modified motor portion of the UPDRS., Results: Twenty participants performed an average of 2.7 tests per day (68.9% adherence) for the study duration (average of 34.4 days) in a home and community setting. The analyses of the five tasks differed between those with Parkinson disease and those without. In discriminating participants with PD from controls, the mean sensitivity was 96.2% (SD 2%) and mean specificity was 96.9% (SD 1.9%). The mean error in predicting the modified motor component of the UPDRS (range 11-34) was 1.26 UPDRS points (SD 0.16)., Conclusion: Measuring PD symptoms via a smartphone is feasible and has potential value as a diagnostic support tool., (Copyright © 2015 Elsevier Ltd. All rights reserved.)

Published
2015
Full Text
View/download PDF

16. Plasma 8-hydroxy-2'-deoxyguanosine Levels in Huntington Disease and Healthy Controls Treated with Coenzyme Q10.

Author

Biglan KM, Dorsey ER, Evans RV, Ross CA, Hersch S, Shoulson I, Matson W, and Kieburtz K

Subjects
8-Hydroxy-2'-Deoxyguanosine, Adult, Aged, Biomarkers blood, Case-Control Studies, Deoxyguanosine blood, Female, Humans, Male, Middle Aged, Oxidative Stress drug effects, Ubiquinone adverse effects, Ubiquinone blood, Ubiquinone therapeutic use, Young Adult, Deoxyguanosine analogs & derivatives, Huntington Disease drug therapy, Ubiquinone analogs & derivatives
Abstract

We analyzed plasma 8OHdG concentrations in 20 individuals enrolled in the Pre-2CARE study before and after treatment with CoQ. Treatment resulted in a mean reduction in 8OHdG of 2.9 ± 2.9 pg/ml for the cohort (p = 0.0003) and 3.0 ± 2.6 pg/ml, for the HD group (p = 0.002). Baseline 8OHdG levels were not different between individuals with HD and controls (19.3 ± 3.2 pg/ml vs. 19.5 ± 4.7 pg/ml, p = 0.87) though baseline CoQ levels were elevated in HD compared with controls (p < 0.001). CoQ treatment reduces plasma 8OHdG and this reduction may serve as a marker of pharmacologic activity of CoQ in HD.

Published
2012
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results